JP2021532148A - 病態および状態の処置に使用するための、エナンチオマー的に精製されたｇｐｅｒアゴニスト - Google Patents

病態および状態の処置に使用するための、エナンチオマー的に精製されたｇｐｅｒアゴニスト Download PDF

Info

Publication number
JP2021532148A
JP2021532148A JP2021504360A JP2021504360A JP2021532148A JP 2021532148 A JP2021532148 A JP 2021532148A JP 2021504360 A JP2021504360 A JP 2021504360A JP 2021504360 A JP2021504360 A JP 2021504360A JP 2021532148 A JP2021532148 A JP 2021532148A
Authority
JP
Japan
Prior art keywords
cancer
srr
derivative
compound
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021504360A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021532148A5 (https=
JPWO2020023391A5 (https=
Inventor
クリストファー ナターレ
パトリック ムーニー
ティナ ガリアンテス
ウェイン ルーク
Original Assignee
リネウス セラピューティクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by リネウス セラピューティクス インコーポレイテッド filed Critical リネウス セラピューティクス インコーポレイテッド
Publication of JP2021532148A publication Critical patent/JP2021532148A/ja
Publication of JP2021532148A5 publication Critical patent/JP2021532148A5/ja
Publication of JPWO2020023391A5 publication Critical patent/JPWO2020023391A5/ja
Priority to JP2024087006A priority Critical patent/JP2024119868A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/19—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/33—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems
    • C07C309/34—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems formed by two rings
    • C07C309/35—Naphthalene sulfonic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2021504360A 2018-07-21 2019-07-22 病態および状態の処置に使用するための、エナンチオマー的に精製されたｇｐｅｒアゴニスト Pending JP2021532148A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024087006A JP2024119868A (ja) 2018-07-21 2024-05-29 病態および状態の処置に使用するための、エナンチオマー的に精製されたｇｐｅｒアゴニスト

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862701726P 2018-07-21 2018-07-21
US62/701,726 2018-07-21
PCT/US2019/042827 WO2020023391A1 (en) 2018-07-21 2019-07-22 Enantiomerically purified gper agonist for use in treating disease states and conditions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024087006A Division JP2024119868A (ja) 2018-07-21 2024-05-29 病態および状態の処置に使用するための、エナンチオマー的に精製されたｇｐｅｒアゴニスト

Publications (3)

Publication Number Publication Date
JP2021532148A true JP2021532148A (ja) 2021-11-25
JP2021532148A5 JP2021532148A5 (https=) 2022-07-29
JPWO2020023391A5 JPWO2020023391A5 (https=) 2022-07-29

Family

ID=69160978

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021504360A Pending JP2021532148A (ja) 2018-07-21 2019-07-22 病態および状態の処置に使用するための、エナンチオマー的に精製されたｇｐｅｒアゴニスト
JP2024087006A Pending JP2024119868A (ja) 2018-07-21 2024-05-29 病態および状態の処置に使用するための、エナンチオマー的に精製されたｇｐｅｒアゴニスト

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024087006A Pending JP2024119868A (ja) 2018-07-21 2024-05-29 病態および状態の処置に使用するための、エナンチオマー的に精製されたｇｐｅｒアゴニスト

Country Status (23)

Country Link
US (6) US20200024262A1 (https=)
EP (2) EP3823617B1 (https=)
JP (2) JP2021532148A (https=)
KR (1) KR20210049778A (https=)
CN (1) CN112469409B (https=)
AU (1) AU2019310029B2 (https=)
BR (1) BR112021001031A2 (https=)
CA (1) CA3107109A1 (https=)
DK (1) DK3823617T3 (https=)
ES (1) ES2980434T3 (https=)
FI (1) FI3823617T3 (https=)
HR (1) HRP20240661T1 (https=)
HU (1) HUE067185T2 (https=)
IL (2) IL312938A (https=)
LT (1) LT3823617T (https=)
MX (2) MX2021000809A (https=)
NZ (1) NZ771952A (https=)
PL (1) PL3823617T3 (https=)
PT (1) PT3823617T (https=)
RS (1) RS65599B1 (https=)
SI (1) SI3823617T1 (https=)
SM (1) SMT202400205T1 (https=)
WO (1) WO2020023391A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022091029A1 (en) * 2020-10-30 2022-05-05 Resverlogix Corp. Methods for lowering hba1c level with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor
US20240376547A1 (en) * 2021-04-08 2024-11-14 Linnaeus Therapeutics, Inc. Oncologic variations associated with cancer and methods of treatment
WO2022245899A2 (en) * 2021-05-19 2022-11-24 Linaeus Therapeutics, Inc. Diagnostic methods and compositions for treatment of cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007019180A2 (en) * 2005-08-04 2007-02-15 Science & Technology Corporation @ Unm Compounds for binding to eralpha/beta and gpr30, methods of treating disease states and conditions mediated through these receptors and identification thereof
WO2016144647A1 (en) * 2015-03-06 2016-09-15 Stc.Unm Method for treating obesity, diabetes, cardiovascular and kidney diseases by regulating gpr30/gper activity
WO2016164450A1 (en) * 2015-04-06 2016-10-13 The Trustees Of The University Of Pennsylvania Compositions and methods for increasing, or preventing or reversing loss of, skin pigmentation in a mammalian subject

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US251870A (en) * 1882-01-03 Automatic gate
US6809104B2 (en) * 2001-05-04 2004-10-26 Tularik Inc. Fused heterocyclic compounds
WO2008153945A2 (en) * 2007-06-06 2008-12-18 University Of South Florida Nutraceutical co-crystal compositions
MX382354B (es) * 2010-11-01 2025-03-13 Celgene Car Llc Compuestos heterocíclicos y usos de los mismos.
US11369618B2 (en) 2016-06-17 2022-06-28 The Trustees Of The University Of Pennsylvania Compounds, compositions and methods for prevention and/or treatment of cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007019180A2 (en) * 2005-08-04 2007-02-15 Science & Technology Corporation @ Unm Compounds for binding to eralpha/beta and gpr30, methods of treating disease states and conditions mediated through these receptors and identification thereof
WO2016144647A1 (en) * 2015-03-06 2016-09-15 Stc.Unm Method for treating obesity, diabetes, cardiovascular and kidney diseases by regulating gpr30/gper activity
WO2016164450A1 (en) * 2015-04-06 2016-10-13 The Trustees Of The University Of Pennsylvania Compositions and methods for increasing, or preventing or reversing loss of, skin pigmentation in a mammalian subject

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
小嶌隆史: "医薬品開発における結晶性選択の効率化を目指して", 薬剤学, vol. 68, no. 5, JPN6009053757, 1 September 2008 (2008-09-01), pages 344 - 349, ISSN: 0005247150 *
杉本功、高橋嘉輝: "溶媒和物、非晶質固体と医薬品製剤", 粉体工学会誌, vol. 22, no. 2, JPN6017004373, 1985, pages 85 - 97, ISSN: 0005247152 *
芦澤一英, 医薬品の多形現象と晶析の科学, JPN6018028449, 2002, pages 56 - 102, ISSN: 0005247151 *
高田則幸: "Ｃｏｃｒｙｓｔａｌのスクリーニングと原薬物性改善への応用", PHARM TECH JAPAN, vol. 25, no. 12, JPN6013060384, 2009, pages 155 - 166, ISSN: 0005247153 *

Also Published As

Publication number Publication date
CN112469409B (zh) 2026-03-13
EP4356913A2 (en) 2024-04-24
US20230382896A1 (en) 2023-11-30
HUE067185T2 (hu) 2024-10-28
SI3823617T1 (sl) 2024-09-30
HRP20240661T1 (hr) 2024-08-16
US20220089576A1 (en) 2022-03-24
MX2024008188A (es) 2024-07-19
NZ771952A (en) 2026-01-30
AU2019310029B2 (en) 2025-05-29
PL3823617T3 (pl) 2024-08-12
US20250171421A1 (en) 2025-05-29
RS65599B1 (sr) 2024-06-28
CN112469409A (zh) 2021-03-09
IL280283A (en) 2021-03-01
IL312938A (en) 2024-07-01
US11760749B2 (en) 2023-09-19
PT3823617T (pt) 2024-06-03
JP2024119868A (ja) 2024-09-03
US20200024262A1 (en) 2020-01-23
WO2020023391A1 (en) 2020-01-30
US20200140417A1 (en) 2020-05-07
EP3823617B1 (en) 2024-03-06
US20220033385A1 (en) 2022-02-03
DK3823617T3 (da) 2024-06-03
US10934277B2 (en) 2021-03-02
SMT202400205T1 (it) 2024-07-09
FI3823617T3 (fi) 2024-05-29
ES2980434T3 (es) 2024-10-01
AU2019310029A1 (en) 2021-02-04
LT3823617T (lt) 2024-07-10
MX2021000809A (es) 2021-06-15
BR112021001031A2 (pt) 2021-04-13
EP4356913A3 (en) 2024-06-26
CA3107109A1 (en) 2020-01-30
KR20210049778A (ko) 2021-05-06
IL280283B1 (en) 2024-06-01
EP3823617A1 (en) 2021-05-26
IL280283B2 (en) 2024-10-01
EP3823617A4 (en) 2022-04-20

Similar Documents

Publication Publication Date Title
CN109563100B (zh) 三唑并嘧啶化合物的晶体形式
AU2014228374B2 (en) CDC7 inhibitors
US20250171421A1 (en) Enantiomerically purified gper agonist for use in treating disease states and conditions
CN106573937A (zh) 作为fshr调节剂的吡唑化合物及其用途
CN110049976A (zh) 布鲁顿氏酪氨酸激酶抑制剂的琥珀酸盐形式和组合物
JP2020515527A (ja) 置換イミダゾール塩系化合物、その調製方法、医薬組成物およびその応用
US20240190904A1 (en) Heteroaryl compounds as inhibitors of RIP2 kinase, composition and application thereof
TW202016091A (zh) 一種ｏｔｒ抑制劑的可藥用鹽、晶型及製備方法
WO2019242646A1 (zh) 催产素受体抑制剂的晶型及其制备方法
WO2025242167A1 (zh) Pkmyt1抑制剂的多晶型、其制备方法及其应用
JP2020508969A (ja) オーロラａキナーゼ選択的阻害剤
IL296700A (en) Process, compositions, and crystalline of substituted pyridinone-pyridinyl compounds

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220721

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220721

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230515

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230525

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230825

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231127

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240129